Table 1.
Included literature characteristics.
| Author and year | Study type | No. of patients | Outcomes | Drugs | |
|---|---|---|---|---|---|
| Carbetocin | Oxytocin | ||||
| Amornpetchakul et al. 2018 [17] | RCT | 176 | 174 | PPH, additional uterotonics, and blood transfusion | Oxytocin: 5 U; intravenous Carbetocin: 100 μg; intravenous |
| Elfayomy 2015 [19] | RCT | 38 | 40 | PPH, additional uterotonics, and blood transfusion | Oxytocin: 50 IU; intravenous Carbetocin: 100 μg; intravenous |
| Maged et al. 2016(A) [18] | RCT | 100 | 100 | PPH, additional uterotonics, and blood transfusion | Oxytocin: 5 IU Carbetocin: 100 μg |
| Maged et al. 2016(B) [15] | RCT | 100 | 100 | PPH, additional uterotonics, and blood transfusion | Oxytocin: 5 IU; per os Carbetocin: 100 μg; per os |
| Nelson et al. 2021 [16] | RCT | 1909 | 1894 | PPH, additional uterotonics, and blood transfusion | Oxytocin: 10 IU; intravenous Carbetocin: 100 μg; intravenous |